Welcome to our dedicated page for TC BioPharm (Holdings) SEC filings (Ticker: TCBPY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TC BioPharm (Holdings) PLC (TCBPY) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Forms 6-K and 15 related to its American Depositary Shares. As a foreign private issuer in the biotechnology sector, TC BioPharm has used these filings to report both operational developments and significant changes to its reporting status under the Securities Exchange Act of 1934.
Through its Form 6-K reports, TC BioPharm has disclosed material corporate events. One filing describes the appointment of joint administrators to TC BioPharm Limited, a subsidiary, with a mandate to explore options for the sale of the subsidiary’s business and assets, including intellectual property and R&D assets, for the benefit of creditors. Another Form 6-K reports that the directors of TC BioPharm (Holdings) PLC resolved to appoint interim liquidators to the parent company and expressed an intention to file Form 15 to deregister its American Depositary Shares, noting that its obligation to file periodic reports would be suspended upon that filing.
The subsequent Form 15 filing is central for investors analyzing TCBPY. This certification and notice confirms the termination of registration of TC BioPharm’s American Depositary Shares under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d) of the Exchange Act. It also identifies the class of securities covered and the approximate number of holders of record at the certification date.
On Stock Titan, these filings can be reviewed alongside AI-powered summaries that explain the implications of each document in plain language. Users can quickly see how appointments of administrators and interim liquidators, as well as deregistration via Form 15, affect TC BioPharm’s regulatory status and the context for the TCBPY symbol.
TC BioPharm (Holdings) plc reports that its directors have resolved to appoint Ben Cairns and Michael Magnay of Alvarez and Marsal Europe LLP as interim liquidators of the company. Addleshaw Goddard LLP has been instructed to file the required court documentation and complete the steps needed to effect the directors’ appointment of these liquidators. The company also plans to file a Form 15 with the U.S. Securities and Exchange Commission to deregister its American Depositary Shares under the Securities Exchange Act of 1934, which will immediately suspend its obligation to file periodic reports once the Form 15 is submitted.
TC BioPharm (Holdings) plc reported that the directors of its subsidiary, TC BioPharm Limited, have appointed joint administrators from Alvarez and Marsal Europe LLP to manage the subsidiary's affairs. The appointed administrators are exploring options to sell the subsidiary's business and assets, explicitly including its intellectual property and R&D assets, with the stated objective of realizing value for creditors. The notice signals that the subsidiary is in formal administration and that future recoveries for creditors will depend on whether a sale or other restructuring can preserve asset value.